23Aug/13

Astellas Pharma launches once-daily oral tacrolimus formulation in US – Pharmaceutical Business Review

Astellas Pharma launches once-daily oral tacrolimus formulation in US
Pharmaceutical Business Review
The new product is indicated for the prophylaxis of organ rejection in patients receiving a kidney transplant used with mycophenolate mofetil (MMF) and corticosteroids, with or without basiliximab induction. Astellas Pharma US president James Robinson
ASTELLAS PHARMA INC : ASTAGRAF XLTM (tacrolimus extended-release 4-traders (press release)
Astellas’ Astagraf XL Launched in U.S. – Analyst BlogNASDAQ
BIZ BRIEF: Astellas announces availability of Astagraf XL capsules in USAsahi Shimbun

all 5 news articles »